Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study

Fig. 1

Association of treatment with hospitalized infections, malignancies and psoriasis in patients with RA. a Abatacept vs other bDMARDs. b Abatacept vs other csDMARDs. *Using inverse probability of treatment weights with further adjustment for time-varying age, disease duration, HAQ-DI, pain and patient global scores, RDCI, and GC treatment duration. bDMARD = biologic disease-modifying antirheumatic drug; CI = confidence interval; csDMARD = conventional synthetic disease-modifying antirheumatic drug; GC = glucocorticoid; HAQ-DI=Health Assessment Questionnaire-Disability Index; HR = hazard ratio; RA = rheumatoid arthritis; RCDI = Rheumatic Disease Comorbidity Index

Back to article page
\